Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: Role of relative serotonin (5-HT) 2A and da D2 antagonism and 5-HT1A partial agonism

Journal of Neurochemistry

Volumn 128, Issue 6, 2014, Pages 938-949

  Huang, Mei ^a   Panos, John J ^a   Kwon, Sunoh ^a   Oyamada, Yoshihiro ^a,b   Rajagopal, Lakshmi ^a   Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

acetylcholine; antipsychotics; dopamine; glutamate; microdialysis; UPLC MS MS

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; BLONANSERIN; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; HOMOVANILLIC ACID; LURASIDONE; N METHYL DEXTRO ASPARTIC ACID; OLANZAPINE; PHENCYCLIDINE; SERINE; SEROTONIN 2A ANTAGONIST; TANDOSPIRONE;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; MALE; MASS SPECTROMETRY; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

RATTUS; RODENTIA;

ACETYLCHOLINE; ANTIPSYCHOTICS; DOPAMINE; GLUTAMATE; MICRODIALYSIS; UPLC-MS/MS;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CEREBRAL CORTEX; DOPAMINE; GLUTAMIC ACID; HIPPOCAMPUS; ISOINDOLES; MALE; MICRODIALYSIS; NEUROTRANSMITTER AGENTS; NUCLEUS ACCUMBENS; PIPERAZINES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SYNAPTIC TRANSMISSION; THIAZOLES;

EID: 84895923611     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12512     Document Type: Article

References (103)

1. Abdul-Monim Z., Reynolds G. P., and, Neill J. C., (2006) The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav. Brain Res. 169, 263-273.
2. Amargõs-Bosch M., Lõpez-Gil X., Artigas F., and, Adell A., (2006) Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int. J. Neuropsychopharmacol. 9, 565-573.
3. Arnsten A. F., (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174, 25-31.
4. Arnsten A. F., Wang M. J., and, Paspalas C. D., (2012) Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron 76, 223-239.
5. Assié M. B., Ravailhe V., Faucillon V., and, Newman-Tancredi A., (2005) Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 315, 265-272.
6. Bonaventure P., Aluisio L., Shoblock J., Boggs J. D., Fraser I. C., Lord B., Lovenberg T. W., and, Galici R., (2011) Pharmacological blockade of serotonin 5-HT7 receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission. PLoS ONE 6, e20210.
7. Bortolozzi A., Díaz-Mataix L., Toth M., Celada P., and, Artigas F., (2007) In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 191, 745-758.
8. de Bruin N. M., van Drimmelen M., Kops M., van Elk J., Wetering M. M., and, Schwienbacher I., (2013) Effects of risperidone, clozapine and the 5-HT(6) antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats. Behav. Brain Res. 244C, 15-28.
9. Calcagno E., Carli M., and, Invernizzi R. W., (2006) The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J. Neurochem. 96, 853-860.
10. Carli M., Calcagno E., Mainolfi P., Mainini E., and, Invernizzi R. W., (2011) Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology 214, 639-652.
11. Cartmell J., Perry K. W., Salhoff C. R., Monn J. A., and, Schoepp D. D., (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40, 847-855.
12. Celada P., Puig M. V., and, Artigas F., (2013) Serotonin modulation of cortical neurons and networks. Front. Integr. Neurosci. 7, 1-20.
13. Chung Y. C., Li Z., Dai J., Meltzer H. Y., and, Ichikawa J., (2004) Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 1023, 54-63.
14. Coyle J. T., Basu A., Benneyworth M., Balu D., and, Konopaske G., (2012) Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb. Exp. Pharmacol. 213, 267-295.
15. Daly D. A., and, Moghaddam B., (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152, 61-64.
16. Dawson L. A., Nguyen H. Q., and, Li P., (2000) In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br. J. Pharmacol. 130, 23-26.
17. Del Arco A., and, Mora F., (2009) Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders. J. Neural. Transm. 116, 941-952.
18. Del Arco A., Segovia G., and, Mora F., (2008) Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity. Psychopharmacology 201, 325-338.
19. Di Matteo V., Di Giovanni G., Di Mascio M., and, Esposito E., (2000) Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res. 865, 85-90.
20. Diaz-Mataix L., Scorza M. C., Bortolozzi A., Toth M., Celada P., and, Artigas F., (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25, 10831-10843.
21. Dringenberg H. C., De Souza-Silva M. A., Rossmuller J., Huston J. P., and, Schwarting R. K., (1998) Histamine H1 receptor antagonists produce increases in extracellular acetylcholine in rat frontal cortex and hippocampus. J. Neurochem. 70, 1750-1758.
22. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., and, Ito A., (2008) Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res. 186, 197-207.
23. Eriksson T. M., Golkar A., Ekström J. C., Svenningsson P., and, Ogren S. O., (2008) 5-HT7 receptor stimulation by 8-OH-DPAT counteracts the impairing effect of 5-HT(1A) receptor stimulation on contextual learning in mice. Eur. J. Pharmacol. 596, 107-110.
24. Frånberg O., Marcus M. M., Ivanov V., Schilström B., Shahid M., and, Svensson T. H., (2009) Asenapine elevates cortical dopamine, noradrenaline and serotonin release. evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology 204, 251-264.
25. Fujii T., Yoshizawa M., Nakai K., Fujimoto K., Suzuki T., and, Kawashima K., (1997) Demonstration of the facilitatory role of 8-OH-DPAT on cholinergic transmission in the rat hippocampus using in vivo microdialysis. Brain Res. 761, 244-249.
26. Gobert A., Rivet J. M., Cistarelli L., Melon C., and, Millan M. J., (1999) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93, 1251-1262.
27. Gołembiowska K., and, Dziubina A., (2002) Inhibition of amino acid release by 5-HT1B receptor agonist in the rat prefrontal cortex. Pol. J. Pharmacol. 54, 625-631.
28. Guzmán-Ramos K., Moreno-Castilla P., Castro-Cruz M., McGaugh J. L., Martínez-Coria H., Laferla F. M., and, Bermúdez-Rattoni F., (2012) Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. Learn. Mem. 19, 453-460.
29. Hamik A., Oksenberg D., Fischette C., and, Peroutka S. J., (1990) Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol. Psychiatry 28, 99-109.
30. Harvey P. D., Ogasa M., Cucchiaro J., Loebel A., and, Keefe R. S., (2011) Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 127, 188-194.
31. Hertel P., Nomikos G. G., Schilström B., Arborelius L., and, Svensson T. H., (1997) Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology 17, 44-55.
32. Homayoun H., and, Moghaddam B., (2007) Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol. Psychiatry 61, 679-687.
33. Horiguchi M., and, Meltzer H. Y., (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology 221, 205-215.
34. Horiguchi M., and, Meltzer H. Y., (2013) Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism. Behav. Brain Res. 247C, 158-164.
35. Horiguchi M., Huang M., and, Meltzer H. Y., (2011) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J. Pharmacol. Exp. Ther. 338, 605-614.
36. Horiguchi M., Hannaway K. E., Adelekun A. E., Jayathilake K., and, Meltzer H. Y., (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 37, 2175-2183.
37. Horisawa T., Ishibashi T., Nishikawa H., Enomoto T., Toma S., Ishiyama T., and, Taiji M., (2011) The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav. Brain Res. 220, 83-90.
38. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., and, Humphrey P. P., (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157-203.
39. Huang M., Li Z., Dai J., Shahid M., Wong E. H., and, Meltzer H. Y., (2008) Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 33, 2934-2945.
40. Huang M., Horiguchi M., Felix A. R., and, Meltzer H. Y., (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. NeuroReport 23, 436-440.
41. Huang M., Felix A. R., Lowe D., Wallace T., Santarelli L., and, Meltzer H. Y,. (in press) The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology.
42. Ichikawa J., Kuroki T., Dai J., and, Meltzer H. Y., (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351, 163-171.
43. Ichikawa J., Ishii H., Bonaccorso S., Fowler W. L., O'Lauqhlin I. A., and, Meltzer H. Y., (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76, 1521-1531.
44. Ichikawa J., Dai J., and, Meltzer H. Y., (2002a) 5-HT1A and 5-HT2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res. 939, 34-42.
45. Ichikawa J., Li Z., Dai J., and, Meltzer H. Y., (2002b) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956, 349-357.
46. Ichikawa J., Dai J., O'Laughlin I. A., Fowler W. L., and, Meltzer H. Y., (2002c) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26, 325-339.
47. Ihalainen J., Sarajärvi T., Kemppainen S., Keski-Rahkonen P., Lehtonen M., and, Tanila H., (2010) A novel delayed non-match to sample object recognition task that allows simultaneous in vivo microdialysis. J. Neurosci. Methods 189, 210-215.
48. ®) on schizophrenia. Nippon Yakurigaku Zasshi 132, 351-360.
49. Ishibashi T., Horisawa T., Tokuda K., et al,. (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 334, 171-181.
50. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., and, Ohno Y., (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 572, 160-170.
51. Javitt D. C., Zukin S. R., Heresco-Levy U., and, Umbricht D., (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr. Bull. 38, 958-966.
52. Jones C. K., Byun N., and, Bubser M., (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37, 16-42.
53. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., and, Altar C. A., (2004) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 483, 45-53.
54. Karoum F., and, Egan M. F., (1992) Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br. J. Pharmacol. 105, 703-707.
55. Koyama T., Nkajima Y., Fujii T., and, Kawashima K., (1999) Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAYx3702 in freely moving rats. Neurosci. Lett. 265, 33-36.
56. Kuroki T., Meltzer H. Y., and, Ichikawa J., (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288, 774-781.
57. Li X. M., Perry K. W., Wong D. T., and, Bymaster F. P., (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136, 153-161.
58. Li Z., Ichikawa J., Dai J., and, Meltzer H. Y., (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493, 75-83.
59. Li Z., Ichikawa J., Huang M., Dai J., and, Meltzer H. Y., (2005) ACP 103, a 5-HT2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology 183, 144-153.
60. Li Z., Huang M., Prus A. J., Dai J., and, Meltzer H. Y., (2007) 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 1134, 70-78.
61. Li Z., Snigdha S., Roseman A. S., Dai J., and, Meltzer H. Y., (2008) Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Eur. J. Pharmacol. 596, 89-97.
62. Liegeois J. F., Ichikawa J., and, Meltzer H. Y., (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947, 157-165.
63. Lõpez-Gil X., Babot Z., Amargõs-Bosch M., Suñol C., Artigas F., and, Adell A., (2007) Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32, 2087-2097.
64. Lõpez-Gil X., Artigas F., and, Adell A., (2009) Role of different monoamine receptors controlling MK801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int. J. Neuropsychopharmacol. 12, 487-499.
65. Martres M. P., Sales N., Bouthenet M. L., and, Schwartz J. C., (1985) Localisation and pharmacological characterisation of D-2 dopamine receptors in rat cerebral neocortex and cerebellum using [125I]iodosulpride. Eur. J. Pharmacol. 118, 211-219.
66. Mauler F., Fahrig T., Horváth E., and, Jork R., (2001) Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Brain Res. 888, 150-157.
67. Meltzer H. Y., (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (2 Suppl), 106S-115S.
68. Meltzer H. Y., (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb. Exp. Pharmacol. 212, 87-124.
69. Meltzer H. Y., and, Huang M., (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog. Brain Res. 72, 177-197.
70. Meltzer H. Y., Rajagapol L., Huang M., Oyamada Y., Kwon S., and, Horiguchi M., (2013) Translating the N-Methyl-D-Aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 16, 2181-2194.
71. Moghaddam B., and, Bunney B. S., (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54, 1755-1760.
72. Mørk A., Witten L. M., and, Arnt J., (2009) Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 206, 39-49.
73. Mutlu O., Ulak G., Celikyurt I. K., Akar F. Y., and, Erden F., (2011) Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol. Biochem. Behav. 98, 398-404.
74. Mutlu O., Celikyurt I. K., Ulak G., Tanyeri P., Akar F. Y., and, Erden F., (2012) Effects of olanzapine and clozapine on radial maze performance in naive and MK-801-treated mice. Arzneimittelforschung 62, 4-8.
75. Nagy K., Marko B., Zsilla G., Matyus P., Pallagi K., Szabo G., Juranyi Z., Barkoczy J., Levay G., and, Harsing L. G., Jr, (2010) Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem. Res. 35, 2096-2106.
76. Nakai K., Fujii T., Fujimoto K., Suzuki T., and, Kawashima K., (1998) Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine- treated rats as measured by in vivo microdialysis. Neurosci. Res. 31, 23-29.
77. Nakamura S., Ago Y., Itoh S., Koyama Y., Baba A., and, Matsuda T., (2005) Effect of zotepine on dopamine, serotonin and noradrenaline release in rat prefrontal cortex. Eur. J. Pharmacol. 528, 95-98.
78. Ohoyama K., Yamamura S., Hamaguchi T., Nakagawa M., Motomura E., Shiroyama T., Tanii H., and, Okada M., (2011) Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 653, 47-57.
79. Paxinos G., and, Watson C., (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, NY.
80. Phillips A. G., Ahn S., and, Floresco S. B., (2004) Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J. Neurosci. 24, 547-553.
81. Saddoris M. P., Sugam J. A., Cacciapaglia F., and, Carelli R. M., (2013) Rapid dopamine dynamics in the accumbens core and shell: learning and action. Front. Biosci. (Elite Ed) 5, 273-288.
82. Salamone J. D., and, Correa M., (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76, 470-485.
83. Schotte A., Janssen P. F., Gommeren W., Luyten W. H., Van Gompel P., Lesage A. S., De Loore K., and, Leysen J. E., (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73.
84. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J. C., and, Meltzer H. Y., (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 332, 622-631.
85. Song P., Mabrouk O. S., Hershey N. D., and, Kennedy R. T., (2012) In vivo neurochemical monitoring using benzoyl chloride derivatization and liquid chromatography-mass spectrometry. Anal. Chem. 84, 412-419.
86. Sprouse J. S., Reynolds L. S., Braselton J. P., Rollema H., and, Zorn S. H., (1999) Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 21, 622-631.
87. Stan A. D., and, Lewis D. A., (2012) Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies. Curr. Pharm. Biotechnol. 13, 1557-1562.
88. Stanley E. M., Wilson M. A., and, Fadel J. R., (2012) Hippocampal neurotransmitter efflux during one-trial novel object recognition in rats. Neurosci. Lett. 511, 38-42.
89. Stip E., Chouinard S., and, Boulay L. J., (2005) On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 219-232.
90. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Kurachi M., Uehara T., Sumiyoshi S., Sumiyoshi C., and, Meltzer H. Y., (2001) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol. Psychiatry 49, 861-868.
91. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., and, Okada M., (2012a) Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br. J. Pharmacol. 165, 1543-1555.
92. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., and, Okada M., (2012b) Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology 62, 765-774.
93. Tao M., Han Y. J., Gao J. F., Tang W. X., Zhu X. Z., Tao D. H., Zhang P., Zou Y., and, Chen H., (2012) Efficacy and safety of tandospirone in the treatment of patients with anxiety disorder. Zhonghua Yi Xue Za Zhi 92, 920-923.
94. Tellez S., Colpaert F., and, Marien M., (1997) Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha 2-adrenoceptor agonists and antagonists. J. Neurochem. 68, 778-785.
95. Watanabe M., and, Hagino Y., (1999) The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum. Eur. J. Pharmacol. 367, 19-23.
96. Watanabe M., Kodama T., and, Hikosaka K., (1997) Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J. Neurophysiol. 78, 2795-2798.
97. Wesołowska A., and, Kowalska M., (2008) Influence of serotonin 5-HT(7) receptor blockade on the behavioral and neurochemical effects of imipramine in rats. Pharmacol. Rep. 60, 464-474.
98. Yamamoto B. K., Pehek E. A., and, Meltzer H. Y,. (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J. Clin. Psychiatry 55 Suppl B, 8-14.
99. Yamamura S., Ohoyama K., Hamaguchi T., et al,. (2009a) Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology 206, 243-258.
100. Yamamura S., Ohoyama K., Hamaguchi T., Nakagawa M., Suzuki D., Matsumoto T., Motomura E., Tanii H., Shiroyama T., and, Okada M., (2009b) Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br. J. Pharmacol. 157, 656-665.
101. Yin D. M., Chen Y. J., Sathyamurthy A., Xiong W. C., and, Mei L., (2012) Synaptic dysfunction in schizophrenia. Adv. Exp. Med. Biol. 970, 493-516.
102. Yoshino T., Nisijima K., Katoh S., Yui K., and, Nakamura M., (2002) Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem. Int. 40, 355-360.
103. Zocchi A., Fabbri D., and, Heidbreder C. A., (2005) Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci. Lett. 387, 157-161.